Human Genome Epidemiology Literature Finder
Records 1 - 6 (of 6 Records) |
Query Trace: Diarrhea and ALK[original query] |
---|
A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 2013 Jun 19 (11): 3068-77. Socinski Mark A, Goldman Jonathan, El-Hariry Iman, Koczywas Marianna, Vukovic Vojo, Horn Leora, Paschold Eugene, Salgia Ravi, West Howard, Sequist Lecia V, Bonomi Philip, Brahmer Julie, Chen Lin-Chi, Sandler Alan, Belani Chandra P, Webb Timothy, Harper Harry, Huberman Mark, Ramalingam Suresh, Wong Kwok-Kin, Teofilovici Florentina, Guo Wei, Shapiro Geoffrey |
Phase 2 Study of the HSP-90 Inhibitor AUY922 in Previously Treated and Molecularly Defined Patients with Advanced Non-Small Cell Lung Cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2018 04 13 (4): 576-584. Felip Enriqueta, Barlesi Fabrice, Besse Benjamin, Chu Quincy, Gandhi Leena, Kim Sang-We, Carcereny Enric, Sequist Lecia V, Brunsvig Paal, Chouaid Christos, Smit Egbert F, Groen Harry J M, Kim Dong-Wan, Park Keunchil, Avsar Emin, Szpakowski Sebastian, Akimov Mikhail, Garon Edward |
Clinical Activity of Pan-HER Inhibitors Against HER2-Mutant Lung Adenocarcinoma. Clinical lung cancer 2018 8 19 (5): e775-e781. Oh In-Jae, Hur Jae Young, Park Cheol-Kyu, Kim Young-Chul, Kim Seung Joon, Lee Min Ki, Kim Hee Joung, Lee Kye Young, Lee Jae Cheol, Choi Chang-M |
Phase 1 Study of Cabozantinib in Japanese Patients With Expansion Cohorts in Non-Small-Cell Lung Cancer. Clinical lung cancer 2019 2 20 (3): e317-e328. Nokihara Hiroshi, Nishio Makoto, Yamamoto Noboru, Fujiwara Yutaka, Horinouchi Hidehito, Kanda Shintaro, Horiike Atsushi, Ohyanagi Fumiyoshi, Yanagitani Noriko, Nguyen Linh, Yaron Yifah, Borgman Anne, Tamura Tomohi |
Efficacy of Brigatinib in Patients With Advanced ALK-Positive NSCLC Who Progressed on Alectinib or Ceritinib: ALK in Lung Cancer Trial of brigAtinib-2 (ALTA-2). Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2022 9 17 (12): 1404-1414. Ou Sai-Hong Ignatius, Nishio Makoto, Ahn Myung-Ju, Mok Tony, Barlesi Fabrice, Zhou Caicun, Felip Enriqueta, de Marinis Filippo, Kim Sang-We, Pérol Maurice, Liu Geoffrey, Migliorino Maria Rita, Kim Dong-Wan, Novello Silvia, Bearz Alessandra, Garrido Pilar, Mazieres Julien, Morabito Alessandro, Lin Huamao M, Yang Hui, Niu Huifeng, Zhang Pingkuan, Kim Edward |
First-in-human phase I study of TQ-B3139 (CT-711) in advanced non-small cell lung cancer patients with ALK and ROS1 rearrangements. European journal of cancer (Oxford, England : 1990) 2022 Sep 173 238-249. Ma Yuxiang, Zhao Hongyun, Xue Jinhui, Liu Li, Yang Nong, Zhang Yang, Yang Haiyan, Hong Shaodong, Xiong Yi, Zhang Zhonghan, Zeng Liang, Pan Hui, Zhou Chunhua, Zhang Yongchang, Wang Xunqiang, Han Xi, Wan Xiaojing, Shao Yang, Liu Jingwen, Yang Yunpeng, Huang Yan, Zhao Yuanyuan, Fang Wenfeng, Li Su, Zhang |
- Page last reviewed:Feb 1, 2024
- Page last updated:Apr 22, 2024
- Content source: